ASTM E2810-23 PDF

Overview

ASTM E2810-23 is the Standard Practice for Demonstrating Capability to Comply with the Test for Uniformity of Dosage Units (UDU), developed by ASTM International. This standard provides a systematic statistical procedure to assess and demonstrate whether pharmaceutical products meet the uniformity of dosage unit criteria as defined in regulatory pharmacopeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). The methodology ensures products maintain consistent dosage unit content, which is essential for pharmaceutical quality control and regulatory compliance.

Key Topics

• Uniformity of Dosage Units (UDU): The degree of consistency in drug content among individual dosage units within a batch, critical for patient safety and product efficacy.
• Two-stage Sampling Test: E2810-23 describes a two-stage statistical sampling plan for UDU, with specific acceptance criteria at each stage, allowing either immediate passing, continuation, or deferral of rejection.
• Acceptance Region and Limit: Acceptance regions for the mean and standard deviation of batch samples are established. Results falling within these regions demonstrate, at a prescribed confidence level, that future samples will likely pass the UDU test.
• Probability and Confidence Level: The procedure estimates a lower bound on the probability that a batch will pass the UDU test, typically at common industry benchmarks (e.g., 90%, 95%, or 99%) and confidence levels (commonly 95%).
• General Applicability: While initially intended for drug content uniformity and dissolution, the methodology is applicable to any multistage test with multiple acceptance criteria.

Applications

ASTM E2810-23 is widely used in pharmaceutical manufacturing and quality control laboratories for:

• Process Validation: Demonstrating a process’s ability to consistently produce units that meet UDU requirements.
• Continuous Process Verification: Providing evidence during ongoing manufacturing that dosage uniformity remains within specification.
• In-Process Testing: Supporting in-line or at-line testing strategies for uniformity throughout production.
• Lot Release Assessments: Supplementing batch evaluation prior to product release, ensuring regulatory requirements are met. However, the methodology is not intended as a substitute for lot or batch release decisions applicable to finished product inspections.
• Regulatory Submissions: Documentation of UDU capability according to globally recognized standards, facilitating compliance with US FDA, EU EMA, and Japanese PMDA regulations.

By applying acceptance limit tables based on sample size, mean, and standard deviation, manufacturers can assert with statistical confidence that future samples from a batch meet UDU criteria.

Related Standards

• ASTM E2709: Practice for Demonstrating Capability to Comply with an Acceptance Procedure - summarizes the statistical fundamentals underpinning E2810 and other similar methodologies.
• USP <905> Uniformity of Dosage Units: The United States Pharmacopeia’s regulatory chapter outlining UDU requirements.
• Ph. Eur. 2.9.40: The European Pharmacopoeia’s parallel chapter on UDU.
• JP 6.02: The Japanese Pharmacopoeia’s corresponding UDU testing standard.
• ASTM E2363: Terminology relating to pharmaceutical and biopharmaceutical manufacturing, guiding definitions used in E2810.

Practical Value

Implementing ASTM E2810-23 enables pharmaceutical organizations to:

• Assure product quality and dosing consistency, thereby enhancing patient safety.
• Meet rigorous, harmonized global standards for dosage unit uniformity, supporting international market access.
• Use data-driven, statistically robust methods to establish, monitor, and demonstrate control over product uniformity throughout the product lifecycle.
• Facilitate transparent, well-documented quality assurance processes for regulatory inspections and audits.

By adhering to ASTM E2810-23, stakeholders in pharmaceutical quality assurance can reliably demonstrate compliance with UDU requirements, underpinning commercial success and regulatory confidence.